तुलना करने के लिए मीट्रिक्स | ENVB | क्षेत्र सेक्टर - संबंधित क्षेत्र की कंपनियों के व्यापक समूह से मेट्रिक्स का औसत हेल्थकेयर | संबंध संबंधENVBपीअर्सक्षेत्र | |
|---|---|---|---|---|
पी/ई अनुपात | −0.5x | −15.7x | −0.3x | |
PEG अनुपात | −0.01 | −0.05 | 0.00 | |
क़ीमत/बुक | 0.8x | 2.9x | 2.6x | |
क़ीमत / एलटीएम बिक्री | - | 1.9x | 2.8x | |
अपसाइड (विश्लेषक लक्ष्य) | - | 104.1% | 66.4% | |
उचित मूल्य अपसाइड | अनलॉक करें | 8.6% | 9.1% | अनलॉक करें |
Enveric Biosciences, Inc., a biotechnology company, focuses on the development of small molecule neuroplastogenic therapeutics that address unmet needs in psychiatric and neurological disorders in the United States. Its lead drug candidate is EB-003, a novel derivative of DMT in preclinical development for mental health indications. The company also develops EVM401 series comprising novel phenylalkylamines and indolethylamines, as well as mescaline-derived compounds to target addiction and neuropsychiatric disorders; and Psybrary, a proprietary library. Enveric Biosciences, Inc. is headquartered in Cambridge, Massachusetts.